Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Whatever Works – Or Might: Pfizer/Wyeth Likely To Keep Both Alzheimer’s Bets

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III bapineuzumab could be shaky and same-stage dimebon possibly more solid, but victory with either could spell ‘blockbuster.’

You may also be interested in...



Antitrust Enforcement Under Obama: Pfizer-Wyeth Offers An Early Test

President Obama pledged to reinvigorate antitrust enforcement during his campaign for the Oval Office. Pfizer's proposed acquisition of Wyeth gives the administration an early opportunity to test that promise

Antitrust Enforcement Under Obama: Pfizer-Wyeth Offers An Early Test

President Obama pledged to reinvigorate antitrust enforcement during his campaign for the Oval Office. Pfizer's proposed acquisition of Wyeth gives the administration an early opportunity to test that promise

Pfizer Backs Out Of Cardiovascular R&D

Drug giant exits obesity, anemia, disease-modifying osteoarthritis and more.

Related Content

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel